PlusTherapeuticsInc . (NASDAQ:PSTV) Short Interest Up 79.9% in July

PlusTherapeuticsInc . (NASDAQ:PSTV) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 262,000 shares, a growth of 79.9% from the June 30th total of 145,600 shares. Based on an average daily trading volume, of 287,600 shares, the days-to-cover ratio is presently 0.9 days. Currently, 6.8% of the company’s shares are sold short.

Several institutional investors and hedge funds have recently modified their holdings of PSTV. Renaissance Technologies LLC boosted its stake in shares of PlusTherapeuticsInc . by 146.6% during the fourth quarter. Renaissance Technologies LLC now owns 85,634 shares of the company’s stock valued at $206,000 after purchasing an additional 50,903 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of PlusTherapeuticsInc . during the fourth quarter valued at $69,000. Finally, Oxford Asset Management LLP purchased a new stake in shares of PlusTherapeuticsInc . during the fourth quarter valued at $50,000. 5.91% of the stock is owned by hedge funds and other institutional investors.

NASDAQ PSTV opened at $2.43 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.18 and a debt-to-equity ratio of 7.34. The company has a fifty day moving average of $2.25 and a two-hundred day moving average of $1.95. The firm has a market capitalization of $9.99 million, a price-to-earnings ratio of -0.12 and a beta of 0.45. PlusTherapeuticsInc . has a 52 week low of $0.93 and a 52 week high of $22.89.

PlusTherapeuticsInc . (NASDAQ:PSTV) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.47. The firm had revenue of $0.12 million for the quarter.

PlusTherapeuticsInc . Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer.

Further Reading: Understanding Average Daily Trade Volume

Receive News & Ratings for PlusTherapeuticsInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PlusTherapeuticsInc . and related companies with's FREE daily email newsletter.